Description
PP2.3 A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: PP2.3 A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation
€2.42
Related products
-
Article: Highlights in genitourinary cancers
€2.42 Add to cart -
Article: Highlights in melanoma
€2.42 Add to cart -
Article: Calendar of events
€2.42 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€2.42 Add to cart
